Home > Journals > Minerva Medica > Past Issues > Articles online first > Minerva Medica 2021 May 05

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Minerva Medica 2021 May 05

DOI: 10.23736/S0026-4806.21.07316-X

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis

Lu WANG 1, 2, Keshuai SUN 1, Ai TIAN 3, Yansheng LIU 1, Miao ZHANG 1, Xinmin ZHOU 1, Ying HAN 1

1 Institute of Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi'an, China; 2 State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, Air Force Medical University, Xi'an, China; 3 Department of Hepatology, the 9th Hospital of Nan chang, Nan chang, China


PDF


BACKGROUND: Fenofibrate (FF) has been suggested as a second-line therapy for primary biliary cholangitis (PBC) with suboptimal response to ursodeoxycholic acid (UDCA). But its long-term effect is unclear.
METHODS: From a retrospective cohort (n=838), we enrolled 106 UDCA-refractory PBC patients, among them 62 received UDCA monotherapy (UDCA group) and 44 received FF combined with UDCA (UDCA+FF group). Changes of liver biochemistries and prognosis after treatment were determined. In addition, sequential liver biopsies were used to assess the effect of FF on histological parameters.
RESULTS: We found adding FF could significantly reduce serum levels of ALP, but for patients with pre-treatment ALP≥1.67 upper limit of normal (ULN), the significant decline of serum ALP was only observed in the UDCA+FF group after 1 year of therapy. The mean GLOBE score and the liver transplant-free survival predicted by GLOBE score were both improved significantly in patients receiving UDCA+FF after 1 year of therapy. The liver-related death or liver transplant calculated using UK-PBC risk score was significantly reduced in patients receiving UDCA+FF after 1 year of therapy. Although there was no marked difference in the final histological analysis after 3 years of therapy, patients receiving UDCA+FF had improvements or stabilization in fibrosis (85.7%), and bile duct loss (78.6%) were more than that of patients receiving UDCA (70.6% and 76.5%, respectively).
CONCLUSIONS: Adding FF improves GLOBE and UK-PBC scores, and is also associated with the improvements or stabilization of disease features, including fibrosis and ductular injury.


KEY WORDS: Fenofibrate; Primary biliary cholangitis; Liver disease; Hepatic

top of page